The duration of the study will include a period for screening of up to a maximum of 28 days, a pretreatment evaluation period of up to 5 days, the on-treatment period, followed by a minimum of 30-day follow-up after the last study drug administration.
The patient may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal.
The study will have 2 parts:
* Part one - Dose Escalation
* Part Two - Expansion. At the defined maximum tolerated doses (MTD(s), additional patients will be enrolled to collect safety, Pharmacokinetic, and Pharmacodynamic data
